ASND vs EW: fair value comparison
Ascendis Pharma A/S and Edwards Lifesciences Corporation · Updated 2026-10-19
ASND reports in EUR, so no same-currency fair-value verdict is published for it. Within Healthcare, ASND currently ranks higher by quality score.
| ASND | EW | |
|---|---|---|
| Verdict | Awaiting full valuation | Undervalued |
| Last price | $227.31 | $85.21 |
| 12-month range | $196.01–$277.18 | $75.87–$95.18 |
| Rank by discount to fair value | — | #33 of 108 Healthcare |
| Rank by quality score | #16 of 301 Healthcare | #17 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | High | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The lower-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: ASND fair value analysis · EW fair value analysis